Masimo Corporation - Common Stock (MASI)

Today the Board of Directors (the “Board”) of Masimo (NASDAQMASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer (“CEO”) of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo’s Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025.

Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 28, 2024 and provided estimates for its full-year 2025 guidance.

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI) concerning whether the board breached its fiduciary duties to shareholders.

Masimo (NASDAQMASI) today announced that its management will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 10:30 a.m. Pacific time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Masimo Corporation (NasdaqGS: MASI).

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Masimo Corporation (NasdaqGS: MASI).

Masimo (NASDAQMASI) today announced that its management will participate in the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 8:30 a.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.

Masimo (NASDAQMASI) today announced that its management will participate in the Jefferies London Healthcare Conference on Thursday, November 21, 2024 at 8:30 a.m. GMT. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.

Masimo (NASDAQMASI) today announced that its management will participate in the Stifel 2024 Healthcare Conference on Monday, November 18, 2024 at 11:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.

Masimo Corporation (Nasdaq: MASI) today announced its financial results for the third quarter ended September 28, 2024.

Masimo (NASDAQMASI) today announced that Vanderbilt University Medical Center (VUMC), a renowned healthcare facility in Nashville, Tennessee, is piloting the use of the Masimo Radius VSM™ patient-worn vital signs monitor with Masimo Patient SafetyNet™ supplemental remote monitoring in the Emergency Department (ED) and nontraditional care spaces. Launched as part of a successful pilot program aimed at tackling the ongoing crisis of emergency room congestion, Radius VSM has been used on hallway beds, in the emergency medical service offload area, and on patients in the waiting room who are typically only monitored periodically – thus providing continuous, wireless monitoring for those who may otherwise be left vulnerable to unexpected deterioration.

Masimo (NASDAQMASI) will release third quarter 2024 financial results for the period ended September 28, 2024, after the market closes on Tuesday, November 5, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Michelle Brennan, interim Chief Executive Officer, Micah Young, Executive Vice President and Chief Financial Officer and Bilal Muhsin, Chief Operating Officer.

Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company’s Board of Directors (the “Board”), effective immediately. Following these appointments, the Board will consist of eight directors.

Today the Board of Directors (the “Board”) of Masimo (Nasdaq: MASI) a leading global medical innovator, provided a series of leadership and business updates:

Politan Capital Management (together with its affiliates, “Politan”), a 9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), today commented on the outcome of the Company’s Annual Meeting of Stockholders (the “Annual Meeting”).

Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), today highlighted that leading proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has updated its earlier report to reiterate its recommendation that shareholders vote FOR the election of Politan’s nominees, Darlene Solomon and Bill Jellison, to the Company’s Board of Directors (the “Board”) at the Annual Meeting of Stockholders (the “Annual Meeting”), set for September 19.

Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), today issued an open letter to shareholders in advance of the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”), set for September 19.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today is sharing a summary of the core issues to consider in this contest for control of the Masimo Board and urging stockholders to vote “FOR” only Masimo’s Director Nominees, Joe Kiani and Christopher Chavez, on the updated GOLD proxy card.

Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), today issued the following statement:

Masimo (NASDAQMASI), a leading global medical innovator, and Qualcomm Technologies, Inc., whose Snapdragon® branded platforms power extraordinary consumer experiences, today announced that Masimo is partnering with Qualcomm Technologies to develop a next-generation smartwatch reference platform for original equipment manufacturers (OEMs) building Wear OS by Google smartwatches. The powerhouse combination of Masimo’s clinically proven, breakthrough biosensing technologies – based on its decades of expertise designing industry-leading hospital monitoring solutions – and best-in-class Snapdragon wearable platforms will help scale the wearable ecosystem. Forging the future of wearable devices, the reference platform will allow OEMs to more efficiently build and bring high-performing, premium smartwatches to market. The platform will also benefit from a robust suite of Masimo health and wellness tracking tools that consumers can trust to provide accurate, reliable data; it will use exclusively high-performance and ultra-low power system-on-a-chips (SoCs) alongside industry-leading wireless and cellular communications from Qualcomm Technologies to enable a superior connectivity experience.

Masimo (NASDAQMASI), a leading global medical innovator, today announced a partnership with Google to develop a new reference platform for original equipment manufacturers (OEMs) building Wear OS by Google™ smartwatches. By incorporating Masimo’s breakthrough biosensing technologies – based on its decades of expertise developing industry-leading hospital monitoring solutions – and standardizing smartwatch devices using the Masimo reference platform, OEMs will be able to more efficiently build and bring high-performing Wear OS smartwatches to market. The robust reference platform is designed to support the fast-growing Wear OS ecosystem – including with a suite of health and wellness tracking tools that consumers can trust to provide accurate, reliable data, seamless integration with Android™ smartphones, and a high-quality, high-performance experience.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today issued a statement following two rulings by the U.S. District Court for the Central District of California (“the Court”): one that finds Politan Capital Management LP (“Politan”) and Quentin Koffey are in contempt of court in connection with their September 12, 2024 violation of a court order, and another that finds Politan made false and misleading statements to stockholders.

Politan Capital Management (together with its affiliates, “Politan”), an 8.9% shareholder of Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), issued a comment from its co-counsel – Schulte Roth & Zabel (“SRZ”) and Munger, Tolles & Olson (“Munger”) – in the California federal court case brought by Masimo seeking to block Politan from voting the proxies it collects.

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today announced that leading proxy advisory firm Egan-Jones has recommended that stockholders vote on the updated GOLD proxy card “FOR” ONLY Masimo’s director nominees – Joe Kiani and Christopher Chavez – in connection with its September 19, 2024 Annual Meeting of Stockholders (the “Annual Meeting”).

Masimo Corporation (“Masimo” or the “Company”) (NASDAQMASI), a global leader in noninvasive monitoring technologies and audio products, today set the record straight in response to Politan Capital Management LP (“Politan”) and Quentin Koffey’s preemptive press release regarding an order from the U.S. District Court for the Central District of California that is still under seal.